Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

515
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of sodium glucose transporters 2-inhibitors on body mass index and systolic blood pressure in kidney transplant recipients with or without diabetes mellitus: a multicenter propensity score-matched analysis.

American journal of nephrology·2026
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

High Protein Diets: What to Tell Our Patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Long-read metagenomics reveals stable resistome and microbiome in treated Italian slaughterhouse wastewater: a preliminary study.

Microbiology spectrum·2026
Same author

[Application of a Sequential Blood Purification Approach in a Complex Critically Ill Patient].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026

Related Experiment Video

Updated: Apr 12, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Lucia Macciò1,2, Elisa Russo1,2, Francesca Costigliolo1

  • 1Unit of Nephrology, Dialysis and Transplantation, IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM) San Martino, Genova, Italy.

Kidney & Blood Pressure Research
|April 10, 2026
PubMed
Summary

Targeted anticomplement therapies offer new hope for kidney diseases driven by complement system overactivation. These advanced treatments aim to reduce inflammation and slow disease progression in conditions like aHUS and C3G.

Keywords:
Anticomplement drugsComplement systemGlomerulonephritisKidney diseases

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.5K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.7K

Related Experiment Videos

Last Updated: Apr 12, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.5K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.7K

Area of Science:

  • Immunology
  • Nephrology
  • Pharmacology

Background:

  • The complement system is crucial for innate immunity but its dysregulation drives kidney diseases.
  • Overactivated complement pathways contribute to atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and other nephropathies.
  • Uncontrolled complement activation leads to renal inflammation, microvascular injury, and fibrosis.

Purpose of the Study:

  • To review the mechanisms, clinical indications, and evidence for targeted anticomplement therapies in kidney diseases.
  • To discuss challenges and future directions in the use of these novel treatments.
  • To highlight the potential of personalized, biomarker-driven approaches.

Main Methods:

  • Review of recent advances in complement biology and therapeutic development.
  • Analysis of clinical trial data and real-world experience with anticomplement drugs.
  • Discussion of safety, cost, and treatment optimization strategies.

Main Results:

  • Development of targeted therapies including C5, C3, factor B/D, C5a receptor, and MASP-2 inhibitors.
  • Evidence from clinical trials supports the efficacy of these agents in various kidney diseases.
  • Ongoing research focuses on optimizing treatment and exploring personalized approaches.

Conclusions:

  • Anticomplement therapies represent a significant advancement in nephrology for complement-mediated kidney diseases.
  • These targeted interventions can improve patient outcomes by reducing disease progression and organ damage.
  • Personalized treatment strategies hold promise for managing complement-driven renal disorders effectively.